Thyroid dysfunction in patients (pts) with metastatic renal cell cancer (RCC) treated with sorafenib

被引：0
|
作者：
Clement, P.
Wolter, P.
Stefan, C.
Decallonne, B.
Dumez, H.
Wildiers, H.
Schoffski, P.
机构：
[1] UZ Leuven, Louvain, Belgium
[2] Katholieke Univ Leuven Hosp, Louvain, Belgium
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
16145
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Thyroid function test (TFT) abnormalities in patients (pts) with metastatic renal cell carcinoma (RCC) treated with sorafenib
    Tamaskar, I. R.
    Unnithan, J.
    Garcia, J. A.
    Dreicer, R.
    Wood, L.
    Iochimescu, A.
    Bukowski, R.
    Rini, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] Axitinib (AG-013736; AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib
    Rini, B. I.
    Wilding, G. T.
    Hudes, G.
    Stadler, W. M.
    Kim, S.
    Tarazi, J. C.
    Bycott, P. W.
    Liau, K. F.
    Dutcher, J. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] Axitinib (AG-013736; AG) in patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sorafenib
    Rini, B.
    Wilding, G.
    Hudes, G.
    Stadler, W. M.
    Kim, S.
    Tarazi, J.
    Bycott, P.
    Liau, K.
    Dutcher, J.
    EJC SUPPLEMENTS, 2007, 5 (04): : 300 - 300
  • [4] Sequential axitinib (AG-013736) therapy of patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sunitinib and sorafenib, cytokines and sorafenib, or sorafenib alone
    Dutcher, J. P.
    Wilding, G.
    Hudes, G. R.
    Stadler, W. M.
    Kim, S.
    Tarazi, J. C.
    Rosbrook, B.
    Rini, B. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] Thyroid Dysfunction in Patients Treated with Tyrosine Kinase Inhibitors, Sunitinib, Sorafenib and Axitinib, for Metastatic Renal Cell Carcinoma
    Daimon, Makoto
    Kato, Tomoyuki
    Kaino, Wataru
    Takase, Kaoru
    Karasawa, Shigeru
    Wada, Kiriko
    Kameda, Wataru
    Susa, Shinji
    Oizumi, Toshihide
    Tomita, Yoshihiko
    Kato, Takeo
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 42 (08) : 742 - 747
  • [6] Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients (pts) with advanced renal cell cancer (RCC)
    Wolter, P.
    Stefan, C.
    Decallonne, B.
    Dumez, H.
    Fieuws, S.
    Wildiers, H.
    Clement, P.
    Debaere, D.
    Van Oosterom, A.
    Schoffski, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib
    Tamaskar, I.
    Bukowski, R.
    Elson, P.
    Ioachimescu, A. G.
    Wood, L.
    Dreicer, R.
    Mekhail, T.
    Garcia, J.
    Rini, B. I.
    ANNALS OF ONCOLOGY, 2008, 19 (02) : 265 - 268
  • [8] A phase II study of depsipeptide (Dep) in patients (pts) with metastatic renal cell cancer (RCC)
    Stadler, WM
    Swerdloff, JN
    Margolin, K
    McCulloch, B
    Thompson, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 420S - 420S
  • [9] Hyperthyroidism and thyroid autoimmunity induced by sorafenib in metastatic renal cell cancer
    Degertekin, Ceyla Konca
    Coskun, Ugur
    Toruner, Fusun Balos
    Akturk, Mujde
    Demirci, Umut
    ENDOCRINE, 2012, 42 (03) : 756 - 757
  • [10] Hyperthyroidism and thyroid autoimmunity induced by sorafenib in metastatic renal cell cancer
    Ceyla Konca Degertekin
    Uğur Coşkun
    Füsun Baloş Törüner
    Müjde Aktürk
    Umut Demirci
    Endocrine, 2012, 42 : 756 - 757
12345